Here are the 10-K annual reports from BioAtla Inc (BCAB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.
BioAtla, Inc. filed an amended annual report to add detailed Part III information on directors, executive compensation, ownership and governance that was originally planned to come from its proxy statement. The amendment does not change prior financial statements but reflects a 50-for-1 share consolidation effective April 6, 2026. As of April 27, 2026, BioAtla had 1,659,612 common shares outstanding. The filing outlines the board’s structure, committee memberships and independence, and describes compensation philosophy emphasizing pay-for-performance and equity incentives. For 2025, the CEO’s base salary was $734,820, other named executives received modest salary increases, and no annual cash bonuses were paid because corporate performance did not meet the 50% threshold under the bonus plan. In March 2025, the compensation committee granted time-vested RSUs to executives and maintained severance and change-in-control protections, stock ownership guidelines, an insider trading policy banning hedging and pledging, and a compensation clawback policy.
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologics (CAB antibodies) for solid tumors, using pH-sensitive designs to concentrate activity in the acidic tumor microenvironment while sparing normal tissue.
The company’s lead programs include CAB bispecific BA3182 in a Phase 1 adenocarcinoma study, CAB-ADC ozuriftamab vedotin (BA3021) targeting ROR2 with plans for a Phase 3 trial in previously treated HPV-associated oropharyngeal cancer, and CAB-ADC mecbotamab vedotin (BA3011) targeting AXL, along with CAB anti-CTLA-4 evalstotug.
On March 2, 2026, the board began a formal process to explore strategic options, including asset sales, licensing, partnerships or other transactions, and implemented a workforce reduction and cost-containment measures. As part of capital preservation, BioAtla is re-evaluating the timing and scope of key clinical programs and the previously announced $40 million ozuriftamab SPV investment structure, even as it highlights a broad patent estate and multiple out-licensing and collaboration agreements.